Hyderabad: Dr Reddy’s Laboratories posted a consolidated 22% jump in profit after tax attributable to equity holders at Rs 1,594 crore for the fourth quarter ended March 31, 2025, as against Rs 1,307 crore in the corresponding quarter of the last financial year.This was on a 20% rise in revenues for Q4FY25 at Rs 8,506 crore compared to Rs 7,083 crore in Q4FY24.The revenues for the quarter included Rs 597 crore from the acquired nicotine replacement therapy (NRT) business. Excluding the NRT business, the underlying growth was 12% year-on-year, the company said.For FY25, the company recorded a marginal 2% increase in PAT at Rs 5,654 crore from Rs 5,568 crore in FY24, despite a 17% rise in revenue to Rs 32,554 crore from Rs 27,916 crore in FY24.